Description
Mechanism of Action
Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.
Absorption: Rapidly absorbed from the GI tract (oral). Peak plasma concentrations in 2-4 hr. Mean oral bioavailability: 64%.
Distribution: Protein-binding: >99%.
Metabolism: Extensively hepatic by CYP3A4, CYP2A6 and CYP2C9 isoenzymes.
Excretion: Principally via faeces; elimination half-life prolonged in mild to moderate hepatic impairment.
MIMS Class
Antihistamines & Antiallergics / Antiasthmatic & COPD Preparations
ATC Classification
R03DC03 – montelukast; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.;
